IncrediMail acquires BizChord

IncrediMail will pay a total of $750,000 for BizChord, including $525,000 in cash and the balance in shares.

By JERUSALEM POST STAFF
December 25, 2006 08:03

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

IncrediMail, a software company specializing in consumer products and services on the Internet, said over the weekend it acquired BizChord Ltd., a Tel Aviv-based transaction processing company that has provided IncrediMail with processing services since 1999. IncrediMail will pay a total of $750,000 for BizChord, including $525,000 in cash and the balance in shares. "We've learned to value BizChord's stellar processing record, and by bringing the online transaction process in-house we will improve user experience, reduce costs and enhance profitability," said IncrediMail CEO Yaron Adler.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS